Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. (Nasdaq: SKYE) generates news primarily through its clinical and corporate progress in metabolic health, with a focus on obesity and overweight. The company regularly issues press releases on its Phase 2a CBeyond™ trial of nimacimab, a peripherally restricted CB1-inhibiting monoclonal antibody, and on related clinical, preclinical, and corporate milestones.
Readers of the SKYE news page can expect updates on topline and extension data from the CBeyond Phase 2a study, including weight loss outcomes, body composition findings, and analyses of rebound weight gain after treatment discontinuation. Skye’s releases have highlighted the performance of nimacimab as a monotherapy and in combination with semaglutide, reporting clinically meaningful additional weight loss, changes in waist circumference, and observations about safety, gastrointestinal tolerability, and neuropsychiatric events.
The company also publishes news on preclinical diet-induced obesity models, where nimacimab has been evaluated alone and with incretin-based therapies such as tirzepatide. These announcements describe weight loss effects, post-treatment weight maintenance, and modulation of metabolic and inflammatory pathways in animal studies. In addition, Skye reports on Phase 1b data in metabolic-associated steatotic liver disease, conference presentations at scientific and medical meetings, and participation in healthcare and investor conferences.
Corporate and regulatory news items include financial results, business updates, and collaboration agreements, such as Skye’s non-exclusive global collaboration and license agreement with Halozyme Therapeutics to use ENHANZE drug delivery technology for higher-dose subcutaneous administration of nimacimab. For investors and observers tracking developments in obesity therapeutics and CB1 inhibition, the SKYE news feed offers a centralized view of Skye’s reported clinical data, preclinical research, partnering activity, and financial disclosures over time.
Skye Bioscience, Inc. (OTCQB: SKYE) has appointed Kaitlyn Arsenault, CPA, as its new Chief Financial Officer. With over 14 years of experience in financial reporting and operations, Arsenault previously served as an independent consultant for emerging companies, including Skye. CEO Punit Dhillon highlighted her expertise in financial controls and reporting as crucial for the company's clinical development and growth objectives. Arsenault expressed commitment to advancing Skye's financial priorities and stakeholder commitments.
Skye Bioscience (SKYE) has successfully closed a registered direct offering, selling 77,777,779 shares of common stock and warrants at an effective price of $0.09 per share, grossing approximately $7 million. The proceeds will support general corporate purposes, including working capital and potential acquisitions. The warrants are exercisable immediately and expire in five years. CEO Punit Dhillon emphasizes that this financing positions the company to advance its drug candidate for glaucoma and enhance its pharmaceutical cannabinoid R&D initiatives, aiming to build shareholder value.
Skye Bioscience (OTCQB: SKYE) has announced a registered direct offering of 77,777,779 shares of its common stock and warrants, priced at $0.09 per share, yielding expected gross proceeds of approximately $7.0 million. The offering is set to close around September 29, 2021. Proceeds will be used for general corporate purposes, including working capital and potential acquisitions. The offering is conducted under an effective SEC registration statement. H.C. Wainwright & Co. serves as the exclusive placement agent.
Skye Bioscience (OTCQB: SKYE) announced that its research partner, the University of Mississippi, will present new preclinical data on its prodrug, THCVHS, at the AAPS PharmSci 360 conference from October 17-20, 2021. The data demonstrates the effectiveness of THCVHS nanoemulsion formulations in lowering intraocular pressure in dutch belted rabbits, especially when used with netarsudil, a rho-kinase inhibitor. Key presentations will occur on October 18 and 19, showcasing the potential of THCVHS in addressing glaucoma, a leading cause of irreversible blindness.
Skye Bioscience, Inc. (OTCQB: SKYE) announced a virtual investor presentation scheduled for October 12, 2021, at 1 p.m. ET, focusing on the company's strategic direction for 2022 and updates on its glaucoma treatment program. The event will feature Skye's management team and advisory board members, followed by a Q&A session. Investors can submit questions by September 28, 2021, and must register in advance to attend. Skye is dedicated to developing cannabinoid-derived therapies for significant health issues, with its lead program targeting glaucoma.
Skye Bioscience, Inc. (OTCQB: SKYE) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CEO Punit Dhillon will present on-demand on September 13 at 7:00 AM ET, accessible via webcast and archived on the company’s Investor Relations site for 90 days. Additionally, Dhillon and senior management will conduct virtual one-on-one meetings with institutional investors during the event. Skye is focused on developing synthetic cannabinoid-derived therapies for unmet medical needs, particularly its lead program targeting glaucoma.
Skye Bioscience (OTCQB: SKYE) announced that Karam Takhar, VP of Corporate Development, will virtually present at the H.C. Wainwright Ophthalmology Conference on August 17 at 7:00 AM ET. The management team will also be available for one-on-one meetings during the event. Skye Bioscience develops cannabinoid-derived therapeutics aimed at addressing unmet medical needs, with its lead program targeting glaucoma, a major cause of blindness. Interested investors should contact their H.C. Wainwright representative for meeting arrangements.
Skye Bioscience has successfully completed genotoxicity studies of its proprietary synthetic cannabinoid THCVHS, a potential treatment for glaucoma. These studies, conducted under Good Laboratory Practices, indicated no chromosomal or gene mutations, a prerequisite for initiating Phase 1 clinical trials in Australia. CEO Punit Dhillon emphasized the significance of these findings for advancing to human trials and noted THCVHS's ability to lower intraocular pressure with minimal systemic exposure.
Skye Bioscience, Inc. (OTCQB: SKYE) has appointed Praveen Tyle, Ph.D., as an independent director to its board. Dr. Tyle brings over 35 years of pharmaceutical industry experience and leadership in various roles. CEO Punit Dhillon expressed confidence in Dr. Tyle's ability to contribute to advancing Skye’s lead clinical program and expanding its development portfolio. Dr. Tyle is currently President and CEO of Invectys and has held senior positions at major pharmaceutical companies. Skye focuses on developing cannabinoid-derived therapies for diseases with significant unmet needs, including glaucoma.
Skye Bioscience, Inc. (OTCQB: SKYE) announced the appointment of Dr. Miguel González-Andrades to its Clinical Advisory Board, a significant move as the company approaches its first-in-human study for THCVHS, targeting glaucoma treatment. CEO Punit Dhillon emphasized the value Dr. González-Andrades brings with his extensive ophthalmology experience. The Clinical Advisory Board also includes renowned experts like Jeffrey Goldberg and Robert Ritch, enhancing the company's capabilities to address unmet medical needs in ophthalmology.